<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Clarithromycin: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int168-clarithromycin.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="bnf_int168-clarithromycin.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int168-clarithromycin.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 07 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a> &gt; <a href="bnf_int127-antibacterials.htm">Antibacterials</a> &gt; <a href="bnf_int166-macrolides.htm">Macrolides</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int167-azithromycin.htm" title="Previous: Azithromycin">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int169-erythromycin.htm" title="Next: Erythromycin">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Clarithromycin</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Clarithromycin</strong> has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1010-aprepitant.htm">Aprepitant</a></td><td><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>aprepitant</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td><p><span>plasma concentration of both drugs increased when </span> <span>clarithromycin</span> <span>given with</span> <span>atazanavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>increases plasma concentration of</span> <span>atorvastatin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1204-cabazitaxel.htm">Cabazitaxel</a></td><td class="cAI"><p><span>avoidance of </span> <span>clarithromycin</span> <span>advised by manufacturer of</span> <span>cabazitaxel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int466-calcium-channel-blockers.htm">Calcium-channel Blockers</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>possibly inhibits metabolism of</span> <span>calcium-channel blockers</span> <span>(increased risk of side-effects)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</p></div></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>increases plasma concentration of</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>inhibits metabolism of</span> <span>ciclosporin</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int483-colchicine.htm">Colchicine</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>possibly increases risk of</span> <span>colchicine</span> <span>toxicity—suspend or reduce dose of <span>colchicine</span> (avoid concomitant use in hepatic or renal impairment)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>enhances anticoagulant effect of</span> <span>coumarins</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>disopyramide</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span>avoidance of </span> <span>clarithromycin</span> <span>advised by manufacturer of</span> <span>dronedarone</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td><p><span>increased risk of rash when </span> <span>clarithromycin</span> <span>given with</span> <span>efavirenz</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int963-eletriptan.htm">Eletriptan</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>increases plasma concentration of</span> <span>eletriptan</span> <span>(risk of toxicity)—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1025-eplerenone.htm">Eplerenone</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>increases plasma concentration of</span> <span>eplerenone</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1135-etravirine.htm">Etravirine</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>increases plasma concentration of</span> <span>etravirine</span> <span>, also plasma concentration of <span>clarithromycin</span> reduced</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1169-everolimus.htm">Everolimus</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>everolimus</span> <span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1119-fesoterodine.htm">Fesoterodine</a></td><td><p><span>manufacturer of fesoterodine advises dose reduction when </span> <span>clarithromycin</span> <span>given with</span> <span>fesoterodine</span> <span>—consult <span>fesoterodine</span> product literature</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1226-fidaxomicin.htm">Fidaxomicin</a></td><td><p><span>avoidance of </span> <span>clarithromycin</span> <span>advised by manufacturer of</span> <span>fidaxomicin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td><p><span></span> <span>clarithromycin</span> <span>increases plasma concentration of</span> <span>itraconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1050-ivabradine.htm">Ivabradine</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>ivabradine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1107-maraviroc.htm">Maraviroc</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>maraviroc</span> <span>(consider reducing dose of <span>maraviroc</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int492-methylprednisolone.htm">Methylprednisolone</a></td><td><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>methylprednisolone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>inhibits metabolism of</span> <span>midazolam</span> <span>(increased plasma concentration  with increased sedation)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int843-nevirapine.htm">Nevirapine</a></td><td><p><span>plasma concentration of </span> <span>clarithromycin</span> <span>reduced by</span> <span>nevirapine</span> <span>(but concentration of an active metabolite increased), also plasma concentration of <span>nevirapine</span> increased</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1118-nilotinib.htm">Nilotinib</a></td><td class="cAI"><p><span>avoidance of </span> <span>clarithromycin</span> <span>advised by manufacturer of</span> <span>nilotinib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int752-omeprazole.htm">Omeprazole</a></td><td><p><span>plasma concentration of both drugs increased when </span> <span>clarithromycin</span> <span>given with</span> <span>omeprazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1186-pazopanib.htm">Pazopanib</a></td><td class="cAI"><p><span>avoidance of </span> <span>clarithromycin</span> <span>advised by manufacturer of</span> <span>pazopanib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span></span> <span>clarithromycin</span> <span>inhibits metabolism of</span> <span>phenytoin</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>clarithromycin</span> <span>given with</span> <span>pimozide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int604-pravastatin.htm">Pravastatin</a></td><td><p><span></span> <span>clarithromycin</span> <span>increases plasma concentration of</span> <span>pravastatin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int824-quetiapine.htm">Quetiapine</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>quetiapine</span> <span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>ranolazine</span> <span>—manufacturer of <span>ranolazine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int855-repaglinide.htm">Repaglinide</a></td><td><p><span></span> <span>clarithromycin</span> <span>enhances effects of</span> <span>repaglinide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>increases plasma concentration of</span> <span>rifabutin</span> <span>(increased risk of toxicity—reduce <span>rifabutin</span> dose)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int199-rifamycins.htm">Rifamycins</a></td><td><p><span>plasma concentration of </span> <span>clarithromycin</span> <span>reduced by</span> <span>rifamycins</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to rifaximin</p></div></td></tr><tr><td><a href="bnf_int1225-rilpivirine.htm">Rilpivirine</a></td><td class="cAI"><p><span>avoidance of </span> <span>clarithromycin</span> <span>advised by manufacturer of</span> <span>rilpivirine</span> <span>(plasma concentration of <span>rilpivirine</span> possibly increased)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>clarithromycin</span> <span>increased by</span> <span>ritonavir</span> <span>(reduce dose of <span>clarithromycin</span> in renal impairment)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>clarithromycin</span> <span>given with</span> <span>saquinavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int858-sildenafil.htm">Sildenafil</a></td><td><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>sildenafil</span> <span>—reduce initial dose of <span>sildenafil</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span> <span>clarithromycin</span> <span>given with</span> <span>simvastatin</span> <span>(avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int921-sirolimus.htm">Sirolimus</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>increases plasma concentration of</span> <span>sirolimus</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>increases plasma concentration of</span> <span>tacrolimus</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int945-tadalafil.htm">Tadalafil</a></td><td><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>tadalafil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>plasma concentration of both drugs possibly increased when </span> <span>clarithromycin</span> <span>given with</span> <span>telaprevir</span> <span>(increased risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>theophylline</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1203-ticagrelor.htm">Ticagrelor</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>ticagrelor</span> <span>—manufacturer of <span>ticagrelor</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1055-tipranavir.htm">Tipranavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>clarithromycin</span> <span>increased by</span> <span>tipranavir</span> <span>(reduce dose of <span>clarithromycin</span> in renal impairment), also <span>clarithromycin</span> increases plasma concentration of <span>tipranavir</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int850-tolterodine.htm">Tolterodine</a></td><td><p><span>avoidance of </span> <span>clarithromycin</span> <span>advised by manufacturer of</span> <span>tolterodine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int255-trazodone.htm">Trazodone</a></td><td><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>trazodone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1085-vinorelbine.htm">Vinorelbine</a></td><td class="cAI"><p><span>possible increased risk of neutropenia when </span> <span>clarithromycin</span> <span>given with</span> <span>vinorelbine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int403-zidovudine.htm">Zidovudine</a></td><td><p><span></span> <span>clarithromycin</span> <span>tablets reduce absorption of</span> <span>zidovudine</span> <span>(give at least 2 hours apart)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</p></div></td></tr></tbody></table><p><strong>Clarithromycin</strong> belongs to <strong>Macrolides</strong> and will have the following interaction information:</p><div class="cG"><p><strong>Note:</strong> See also Telithromycin</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td class="cAI"><p><span>avoidance of </span> <span>macrolides</span> <span>advised by manufacturer of</span> <span>artemether/lumefantrine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int556-bromocriptine.htm">Bromocriptine</a></td><td><p><span></span> <span>macrolides</span> <span>possibly increase plasma concentration of</span> <span>bromocriptine</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int557-cabergoline.htm">Cabergoline</a></td><td><p><span></span> <span>macrolides</span> <span>possibly increase plasma concentration of</span> <span>cabergoline</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>macrolides</span> <span>possibly inhibit metabolism of</span> <span>ciclosporin</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>macrolides</span> <span>increase plasma concentration of</span> <span>digoxin</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1152-droperidol.htm">Droperidol</a></td><td class="cAI"><p><span>avoidance of </span> <span>macrolides</span> <span>advised by manufacturer of</span> <span>droperidol</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int563-ergotamine-and-methysergide.htm">Ergotamine and Methysergide</a></td><td class="cAI"><p><span>increased risk of ergotism when </span> <span>macrolides</span> <span>given with</span> <span>ergotamine and methysergide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int841-mizolastine.htm">Mizolastine</a></td><td class="cAI"><p><span></span> <span>macrolides</span> <span>possibly inhibit metabolism of</span> <span>mizolastine</span> <span>(avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int231-reboxetine.htm">Reboxetine</a></td><td class="cAI"><p><span>avoidance of </span> <span>macrolides</span> <span>advised by manufacturer of</span> <span>reboxetine</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Clarithromycin</strong> belongs to <strong>Antibacterials</strong> and will have the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1058-typhoid-vaccine-oral.htm">Typhoid Vaccine (oral)</a></td><td><p><span></span> <span>antibacterials</span> <span>inactivate</span> <span>oral typhoid vaccine</span> <span>—see under Typhoid vaccines, <a title="monograph-family: Typhoid vaccines" href="PHP8409-typhoid-vaccines.htm">section 14.4</a></span>  </p></td><td></td></tr></tbody></table></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int167-azithromycin.htm">Previous: Azithromycin</a> | <a class="top" href="bnf_int168-clarithromycin.htm#">Top</a> | <a accesskey="]" href="bnf_int169-erythromycin.htm">Next: Erythromycin</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>